Factors That Affect Symptoms of Injection Site Infection among Japanese Patients Who Self-Inject Insulin for Diabetes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Questionnaire Development
2.3.1. Clinical and Demographic Characteristics (7 Items)
2.3.2. Injection Site Disinfection Practice (2 Items)
2.3.3. Infection Experience (2 Items)
2.3.4. Safety Issues (4 Items)
2.4. Statistical Analysis
2.5. Ethics
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- O’Grady, N.P.; Alexander, M.; Burns, L.A.; Dellinger, E.P.; Garland, J.; Heard, S.O.; Lipsett, P.A.; Masur, H.; Mermel, L.A.; Pearson, M.L.; et al. Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Am. J. Infect. Control 2011, 39, S1–S34. [Google Scholar] [CrossRef] [Green Version]
- World Health Organization. WHO Best Practices for Injections and Related Procedures Toolkit; Safe Injection Global Network (SIGN); World Health Organization: Geneva, Switzerland, 2010; Available online: https://apps.who.int/iris/handle/10665/44298 (accessed on 9 February 2021).
- Forum for Injection Technique UK. The UK Injection and Infusion Technique Recommendations, 4th ed.; Becton, Dickinson UK Ltd.: Winnersh, UK, 2016; Available online: http://www.fit4diabetes.com (accessed on 9 February 2021).
- Department of Health, Australian Government. Administration of Vaccines. 2019. Available online: https://immunisationhandbook.health.gov.au/vaccination-procedures/administration-of-vaccines (accessed on 10 February 2021).
- Wong, H.; Moss, C.; Moss, S.M.; Shah, V.; Halperin, S.A.; Ito, S.; Mithal, P.; Qu, A.; Taddio, A. Effect of alcohol skin cleansing on vaccination-associated infections and local skin reactions: A randomized controlled trial. Hum. Vaccines Immunother. 2019, 15, 995–1002. [Google Scholar] [CrossRef] [Green Version]
- Hutin, Y.; Hauri, A.; Chiarello, L.; Catlin, M.; Stilwell, B.; Ghebrehiwet, T.; Garner, J. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bull. World Health Organ. 2003, 81, 491–500. [Google Scholar]
- Frid, A.H.; Kreugel, G.; Grassi, G.; Halimi, S.; Hicks, D.; Hirsch, L.J.; Smith, M.J.; Wellhoener, R.; Bode, B.W.; Hirsch, I.B.; et al. New insulin delivery recommendations. Mayo Clin. Proc. 2016, 91, 1231–1255. [Google Scholar] [CrossRef] [Green Version]
- Niaz, F.; Bashir, F.; Shams, N.; Shaikh, Z.; Ahmed, I. Cutaneous manifestations of diabetes mellitus type 2: Prevalence and association with glycemic control. J. Pak. Assoc. Dermatol. 2016, 26, 4–11. [Google Scholar]
- De Macedo, G.M.C.; Nunes, S.; Barreto, T. Skin disorders in diabetes mellitus: An epidemiology and physiopathology review. Diabetol. Metab. Syndr. 2016, 8, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Koivisto, V.A.; Felig, P. Is skin preparation necessary before insulin injection? Lancet 1978, 20, 1072–1073. [Google Scholar] [CrossRef]
- McCarthy, J.A.; Covarrubias, B.; Sink, P. Is the traditional alcohol wipe necessary before an insulin injection? Diabetes Care 1993, 16, 402. [Google Scholar] [CrossRef] [PubMed]
- Blanco, M.; Hernández, M.T.; Strauss, K.W.; Amaya, M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013, 39, 445–453. [Google Scholar] [CrossRef] [PubMed]
- Pozzuoli, G.M.; Laudato, M.; Barone, M.; Crisci, F.; Pozzuoli, B. Errors in insulin treatment management and risk of lipohypertrophy. Acta Diabetol. 2018, 55, 67–73. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, Y.; Yano, R. The necessity of skin disinfection before subcutaneous injection: An integrative literature review. Jpn. J. Nurs. Art Sci. 2014, 13, 140–147. (In Japanese) [Google Scholar] [CrossRef]
- Faul, F.; Erdfelder, E.; Buchner, A.; Lang, A.G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav. Res. Methods 2009, 41, 1149–1160. [Google Scholar] [CrossRef] [Green Version]
- Ryu, C.S.; Oh, S.H.; Lee, K.O.; Park, H.S.; An, H.J.; Lee, J.Y.; Ko, E.J.; Park, H.W.; Kim, O.J.; Kim, N.K. MiR-10a, 27a, 34b/c, and 300 Polymorphisms are Associated with Ischemic Stroke Susceptibility and Post-Stroke Mortality. Life 2020, 10, 309. [Google Scholar] [CrossRef] [PubMed]
- Frid, A.; Hirsch, L.; Gaspar, R.; Hicks, D.; Kreugel, G.; Liersch, J.; Letondeur, C.; Sauvanet, J.P.; Tubiana-Rufi, N.; Strauss, K.; et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010, 36, S3–S18. [Google Scholar] [CrossRef]
- Dryden, M.S. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 2010, 65, 35–44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- American Diabetes Association. Insulin administration. Diabetes Care 2004, 27, S106–S107. [Google Scholar] [CrossRef] [Green Version]
- Yoshida, Y.; Yano, R. A description of content on skin disinfection before subcutaneous injection in nursing skills and techniques books. J. Compr. Nurs. Res. 2020, 19, 11–19. (In Japanese) [Google Scholar]
- O’Neill, J.; Grinager, H.; Smith, S.D.; Sibley, S.; Harrison, A.R.; Lee, M.S. Isopropyl alcohol skin antisepsis does not reduce incidence of infection following insulin injection. Am. J. Infect. Control. 2013, 41, 755–756. [Google Scholar] [CrossRef]
- Potter, P.A.; Perry, A.G.E.; Hall, A.E.; Stockert, P.A. Fundamentals of Nursing; Mosby Elsevier: St. Louis, MO, USA, 2017. [Google Scholar]
- Wey, S.J.; Chen, D.Y. Common cutaneous disorders in the elderly. J. Clin. Gerontol. Geriatr. 2010, 1, 36–41. [Google Scholar] [CrossRef] [Green Version]
- Small, W.; Rhodes, T.; Wood, E.; Kerr, T. Public injection settings in Vancouver: Physical environment, social context and risk. Int. J. Drug Policy 2007, 18, 27–36. [Google Scholar] [CrossRef]
- Rhodes, T.; Watts, L.; Davies, S.; Martin, A.; Smith, J.; Clark, D.; Craine, N.; Lyons, M. Risk, shame and the public injector: A qualitative study of drug injecting in South Wales. Soc. Sci. Med. 2007, 65, 572–585. [Google Scholar] [CrossRef]
- Strauss, K.; De Gols, H.; Hannet, I.; Partanen, T.M.; Frid, A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract. Diabetes 2002, 19, 71–76. [Google Scholar] [CrossRef]
Variable | All (n = 238) (%) | Disinfection (n = 198) (%) | No Disinfection (n = 40) (%) | p-Value |
---|---|---|---|---|
Sex | ||||
Male | 125 (52.5) | 100 (50.5) | 25 (62.5) | 0.224 |
Female | 113 (47.5) | 98 (49.5) | 15 (34.3) | |
Age, years | 63.88 ± 12.92 | 63.77 ± 12.89 | 60.00 ± 11.62 | 0.064 |
Duration of diabetes, years | 17.48 ± 11.29 | 17.34 ± 11.13 | 17.66 ± 12.19 | 0.901 |
HbA1c, % | 7.84 ± 1.42 | 7.73 ± 1.37 | 8.38 ± 1.53 | 0.016 |
Injections/day | 2.69 ± 1.27 | 2.65 ± 1.29 | 2.90 ± 1.15 | 0.259 |
Perception of disinfection importance | ||||
Necessary | 211 (88.7) | 195 (98.5) | 16 (40.0) | 0.001 |
Unnecessary | 27 (11.3) | 3 (1.5) | 24 (60.0) | |
Infection symptoms | ||||
Yes | 68 (28.6) | 60 (30.3) | 8 (20.0) | 0.250 |
No | 170 (71.4) | 138 (69.7) | 32 (80.0) | |
Employed | ||||
Yes | 98 (41.2) | 75 (37.9) | 23 (57.5) | 0.034 |
No | 140 (58.8) | 123 (62.1) | 17 (42.5) | |
Injections outside the home | ||||
Yes | 166 (69.7) | 134 (67.7) | 32 (80.0) | 0.135 |
No | 72 (30.3) | 64 (32.3) | 8 (20.0) | |
Type of diabetes | ||||
Type 1 | 52 (21.8) | 41 (20.7) | 11 (25.0) | 0.636 |
Type 2 | 140 (58.8) | 118 (59.6) | 22 (55.0) | |
Unknown | 46 (19.3) | 41 (20.7) | 7 (17.5) | |
Needle re-use | ||||
No | 221 (92.9) | 188 (94.9) | 33 (82.5) | 0.012 |
Yes | 17 (7.1) | 10 (5.1) | 7 (17.5) | |
Showering or bathing | ||||
Every day | 91 (38.2) | 76 (38.4) | 15 (37.5) | 0.815 |
Every 2–3 days | 129 (54.2) | 108 (54.5) | 21 (52.5) | |
Every ≥4 days | 18 (7.6) | 14 (7.0) | 4 (10.0) |
Variable | All (n = 238) (%) | Infection Symptoms (n = 68) (%) | No Infection Symptoms (n = 170) (%) | p-Value |
---|---|---|---|---|
Sex | ||||
Male | 125 (52.5) | 28 (41.2) | 97 (57.1) | 0.031 |
Female | 113 (47.5) | 40 (58.8) | 73 (42.9) | |
Age, years | 63.22 ± 12.77 | 57.22 ± 14.09 | 65.63 ± 11.39 | 0.001 |
Duration of diabetes, years | 17.48 ± 11.29 | 15.02 ± 11.26 | 18.33 ± 11.19 | 0.075 |
HbA1c, % | 7.84 ± 1.42 | 7.93 ± 1.35 | 7.80 ± 1.45 | 0.549 |
Disinfection of injection site | ||||
Yes | 203 (85.3) | 63 (92.6) | 141 (82.9) | 0.150 |
No | 35 (17.7) | 6 (8.8) | 29 (17.0) | |
Injections/day | 2.69 ± 1.27 | 3.10 ± 1.22 | 2.53 ± 1.25 | 0.001 |
Employed | ||||
Yes | 98 (41.2) | 30 (44.1) | 68 (40.0) | 0.664 |
No | 140 (58.8) | 39 (57.4) | 102 (60.0) | |
Injections performed outside the home | ||||
Yes | 166 (69.7) | 58 (85.3) | 108 (63.5) | 0.001 |
No | 72 (30.3) | 10 (14.7) | 62 (36.5) | |
Type of diabetes | ||||
Type 1 | 52 (21.8) | 24 (35.3) | 28 (16.5) | 0.017 |
Type 2 | 140 (58.8) | 35 (51.5) | 106 (62.4) | |
Unknown | 46 (19.3) | 10 (14.7) | 36 (21.2) | |
Needle re-use | ||||
No | 221 (92.9) | 59 (86.8) | 162 (95.3) | 0.028 |
Yes | 17 (7.1) | 9 (13.2) | 8 (4.7) | |
Showering or bathing | ||||
Every day | 91 (38.2) | 35 (51.5) | 57 (33.5) | 0.028 |
Every 2–3 days | 126 (52.9) | 28 (41.2) | 101 (59.4) | |
Every ≥4 days | 18 (7.6) | 6 (8.8) | 12 (7.1) |
Variable | Forward Stepwise Selection | Forced Entry | ||||
---|---|---|---|---|---|---|
OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
Disinfection of injection site | 2.552 | 1.044–6.243 | 0.040 | 2.492 | 0.999–6.216 | 0.050 |
Age | 0.950 | 0.928–0.973 | 0.001 | 0.955 | 0.955–0.930 | 0.001 |
Injection outside the home | 3.055 | 1.412–6.606 | 0.005 | 2.728 | 1.153–6.455 | 0.022 |
Sex | - | - | 0.068 | - | 0.904–3.143 | 0.100 |
Type of diabetes | - | - | 0.111 | - | 0.427–1.175 | 0.182 |
Injection/day | - | - | 0.260 | - | 0.825–1.471 | 1.102 |
Hygiene habits | - | - | 0.841 | - | 0.611–1.825 | 0.845 |
Hosmer–Lemeshow test Percentage of correct classifications | p = 0.475 73.1% | p = 0.269 77.3% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoshida, Y.; Sumikawa, M.; Sugimori, H.; Yano, R. Factors That Affect Symptoms of Injection Site Infection among Japanese Patients Who Self-Inject Insulin for Diabetes. Healthcare 2021, 9, 402. https://doi.org/10.3390/healthcare9040402
Yoshida Y, Sumikawa M, Sugimori H, Yano R. Factors That Affect Symptoms of Injection Site Infection among Japanese Patients Who Self-Inject Insulin for Diabetes. Healthcare. 2021; 9(4):402. https://doi.org/10.3390/healthcare9040402
Chicago/Turabian StyleYoshida, Yuko, Masuko Sumikawa, Hiroyuki Sugimori, and Rika Yano. 2021. "Factors That Affect Symptoms of Injection Site Infection among Japanese Patients Who Self-Inject Insulin for Diabetes" Healthcare 9, no. 4: 402. https://doi.org/10.3390/healthcare9040402
APA StyleYoshida, Y., Sumikawa, M., Sugimori, H., & Yano, R. (2021). Factors That Affect Symptoms of Injection Site Infection among Japanese Patients Who Self-Inject Insulin for Diabetes. Healthcare, 9(4), 402. https://doi.org/10.3390/healthcare9040402